Current medical research and opinion
-
Randomized Controlled Trial
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-label extension. ⋯ Galcanezumab was effective, safe, and well-tolerated, with high adherence, for up to 12 months of treatment in patients with chronic migraine.
-
Network meta-analysis was used to derive estimates of the relative efficacy of inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and/or at increased cardiovascular risk due to elevated low-density lipoprotein cholesterol taking maximum tolerated dose statins. ⋯ This study provides insight regarding the comparative efficacy of drugs for which no head-to-head trials exist and suggests that inclisiran, alirocumab, and evolocumab are expected to provide similar clinically meaningful improvements in low-density lipoprotein cholesterol in patients with hypercholesterolemia on maximally tolerated statins who are at increased cardiovascular risk.
-
Randomized Controlled Trial
Migraine history and response to lasmiditan across racial and ethnic groups.
The robust enrollment in SPARTAN and SAMURAI provided the opportunity to present post-hoc descriptive details on migraine disease characteristics and treatment outcomes after treatment with lasmiditan, a selective serotonin (5-HT1F) receptor agonist, in racial and ethnic subgroups. ⋯ There were few differences in demographic and clinical characteristics across racial and ethnic groups. Similar lasmiditan efficacy and safety outcomes were observed in AA versus W participants, and in HL versus Non-HL participants. Small observed differences may be driven by a tendency toward a more positive response observed across all treatment groups by AA and HL participants.
-
We developed a patient- and family-centered traumatic brain injury (TBI) transitional care intervention, called BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery), to improve quality of life (via SF-36) of younger TBI patients of different racial groups discharged home from acute hospital care and caregivers. We describe our design, methods, and baseline characteristics for our feasibility study. ⋯ BETTER is among the first TBI transitional care intervention to address needs/preferences for younger TBI patients of different racial groups after discharge home from acute hospital care and families. Findings can be used to inform future work.
-
Clinical Decision Support Systems (CDSSs) are computer-based tools intended to support physicians in clinical decision making. MilleDSS is an illustrative example for the Italian context. It is featured by four domains of GP-software interaction, such as clinical management and follow-up evaluation, prescribing appropriateness and clinical risk, prevention strategies and medical computerized stewardship on scientific update and training. ⋯ The Medical Device Regulation (MDR: (EU) 2017/745) indicates that clinical evidence needs to be provided for any software intended to medical purpose. Clinical research on CDSS effectiveness will be therefore conducted through epidemiological studies. In theory, this generation of evidence would follow the pyramid of evidence as per medications approval but, given the large use and constant update of CDSS for daily clinical practice, attentions should be posed on the most cost-effective study.